ERK reactivation under MEK inhibition has been reported to be the main problem in therapeutic strategies aimed at NRAS and KRAS mutant tumours [83], with ERK being the critical node between responsiveness to MEK inhibition and MAPK reactivation. The gene discussed is MAPK1; the disease is neoplasm.